X-ZELL

X-ZELL

Enabling same-day cancer diagnostics from minimally invasive sample material

Founded 2014

Singapore 19 employees Seed Total: $5.56M Biotechnology, Health Care +1

X-ZELL is an award-winning medical technology start-up specializing in next-generation cytology. Cytology – or cytopathology – is the science of diagnosing diseases by examining single atypical cells or cell clusters. X-ZELL has developed a plug-and-play solution for the detection, visualization, and digitization of these phenomena in minimally invasive body liquids. Slotting seamlessly into clinical routine, it does not require complex specimen preparation and reduces the average time from sample to diagnosis from 48h to less than 4h. The result: better diagnostics and improved patient care. X-ZELL is headquartered in Singapore and has regional offices in Germany (Europe), Thailand (Southeast Asia), and the US (North America). As of the latest available data of 01 May 2018, X-ZELL has secured a $4.00M Seed Round investment from investors including Essex Bio-Technology, DIAG Deutsche Industrieanlagen, Kurt Heinrichs, Frank Ulmer, and Frederik Vandermarlie. X-ZELL operates in the Biotechnology and Healthcare industries, aiming to revolutionize cancer diagnostics by enabling same-day results from minimally invasive sample materials, showcasing potential for significant impact on patient care and disease management. X-ZELL's innovative approach to cancer diagnostics could disrupt the traditional methods, offering a faster and more efficient alternative. With a global presence, the startup is well-positioned to address the critical need for rapid and accurate diagnostics in the healthcare industry. This, combined with a strong investor backing, sets the stage for X-ZELL to drive substantial change and potentially deliver significant returns for its investors in the future.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round X	$4.00M	5	Essex Bio-Technology, DIAG Deutsche Industrieanlagen +3	01 May 2018
Seed Round X	$1.26M	5	Y Combinator, Feng Hu +3	22 Mar 2016
Pre Seed Round X	$200.00K	-		01 Nov 2015
Pre Seed Round X	$100.00K	-		01 Jan 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round X

$4.00M

Essex Bio-Technology, DIAG Deutsche Industrieanlagen +3

01 May 2018

Seed Round X

$1.26M

Y Combinator, Feng Hu +3

22 Mar 2016

Pre Seed Round X

$200.00K

01 Nov 2015

Pre Seed Round X

$100.00K

01 Jan 2015

FAQ About X-ZELL

Enabling same-day cancer diagnostics from minimally invasive sample material

X-ZELL was founded in 2014.

X-ZELL is headquartered in Singapore.

X-ZELL operates in Biotechnology, Health Care and Medical Devices. Its work centres on Medical Technology, Cytology, Cancer Diagnostics and Liquid Biopsy.

X-ZELL has approximately 19 employees.

X-ZELL has completed 4 funding rounds, raising a total of $5.56M. The latest funding stage is Seed.

Top alternatives and competitors to X-ZELL include CellMax Life, RainDance Technologies, GeneCast Biotechnology Co., Ltd., Rarecells , RhoDx, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

X-ZELL and CellMax Life are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About X-ZELL

Funding Rounds & Investors (4)

X-ZELL Alternatives & Competitors

FAQ About X-ZELL